ERBB2 and gastric cancer: As we know, HER2 has been found to be a predictive marker to HER2-targeted therapy in breast and gastric cancer; therefore, routine test for HER2 status is mandatory in these tumors (Calhoun & Collins, 2015; Jiang et al., 2018).